Anemia is common in patients with chronic kidney disease and is associated with a high
burden of morbidity and adverse clinical outcomes. In 2012, Kidney Disease: Improving …

Chronic kidney disease (CKD) affects approximately 10% of the worldwide population;
anaemia is a frequent complication. Inadequate erythropoietin production and absolute or …

Introduction Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase
inhibitor being developed for the treatment of anemia of chronic kidney disease (CKD). This …

For the past 3 decades, erythropoiesis-stimulating agents (ESA) in conjunction with iron
supplementation has been the mainstay of treatment for anemia in chronic kidney disease …

The production of erythropoietin (EPO), the main regulator of erythroid differentiation, is
regulated by hypoxia-inducible factor (HIF). HIF2α seems to be the principal regulator of …

Background Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are new
therapeutic agents for anaemia in chronic kidney disease (CKD). We evaluated by meta …

Aim: We performed a systematic review and network meta-analysis evaluating the safety
and efficacy of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) among …

Background Chronic inflammation, reflected by an increased blood C-reactive protein (CRP)
level, is common in patients with chronic kidney disease (CKD) and is involved in the …

Background Renal anemia is caused by end-stage renal disease (ESRD) but has a complex
etiology. The application of dietary fiber (DF) to regulate the gut microbiota has shown …

Background Renal anemia of diabetic kidney disease (DKD) shows higher incidence rate,
earlier onset and higher severity than other chronic kidney disease (CKD). Roxadustat, an …